An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors
Latest Information Update: 24 Nov 2022
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 01 Dec 2022 Results published in the Cancer Chemotherapy and Pharmacology
- 21 May 2020 Status changed from active, no longer recruiting to completed.
- 27 Feb 2020 Planned End Date changed from 1 Jun 2020 to 31 May 2020.